Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.
Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be staged with a positron emission tomography (PET) scan and what follow-up scans are needed.
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.
Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.
James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the ability to treat patients.
Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.
